Boston Scientific — Oct 22, 2025 release

BOSTON SCIENTIFIC CORPORATION NON-GAAP NET INCOME AND NET INCOME PER SHARE RECONCILIATIONS (Unaudited) Nine Months Ended September 30, 2025 (in millions, except per share data) Gross Profit Operating Expenses Operating Income (Loss) Other Income (Expense) Income (Loss) Before Income Taxes Net Income (Loss) Net Income (Loss) Attributable to Noncontrolling Interests Net Income (Loss) Attributable to Boston Scientific Common Stockholders Impact per Share Reported $ 10,175   $ 7,387   $ 2,788   $ (103) $ 2,685   $ 2,222   $ (4) $ 2,226   $ 1.49   Non-GAAP adjustments: Amortization expense —  (669) 669  —  669  576  7  570  0.38  Goodwill and other intangible asset impairment charges —  (46) 46  —  46  37  —  37  0.02  Acquisition/divestiture-related net charges (credits) 159  (226) 385  (229) 156  157  —  157  0.10  Restructuring and restructuring-related net charges (credits) 84  (162) 247  —  247  215  —  215  0.14  Investment portfolio net losses (gains) and impairments —  —  —  (0) (0) (0) —  (0) (0.00) EU MDR implementation costs 22  (11) 34  —  34  29  —  29  0.02  Deferred tax expenses (benefits) —  —  —  —  —  139  —  139  0.09  Discrete tax items —  —  —  —  —  1  —  1  0.00  Adjusted $ 10,440   $ 6,272   $ 4,168   $ (332) $ 3,836   $ 3,375   $ 3   $ 3,372   $ 2.26   Nine Months Ended September 30, 2024 (in millions, except per share data) Gross Profit Operating Expenses Operating Income (Loss) Other Income (Expense) Income (Loss) Before Income Taxes Net Income (Loss) Net Income (Loss) Attributable to Noncontrolling Interests Net Income (Loss) Attributable to Boston Scientific Common Stockholders Impact per Share Reported $ 8,395   $ 6,467   $ 1,928   $ (231) $ 1,697   $ 1,284   $ (4) $ 1,288   $ 0.87   Non-GAAP adjustments: Amortization expense —  (631) 631  —  631  545  7  539  0.36  Goodwill and other intangible asset impairment charges —  (276) 276  —  276  243  —  243  0.16  Acquisition/divestiture-related net charges (credits) 49  (207) 255  1  256  315  —  315  0.21  Restructuring and restructuring-related net charges (credits) 83  (65) 149  —  149  129  —  129  0.09  Investment portfolio net losses (gains) and impairments —  —  —  17  17  17  —  17  0.01  EU MDR implementation costs 27  (12) 39  —  39  34  —  34  0.02  Deferred tax expenses (benefits) —  —  —  —  —  120  —  120  0.08  Adjusted $ 8,553   $ 5,275   $ 3,278   $ (213) $ 3,065   $ 2,685   $ 2   $ 2,683   $ 1.81   An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document. Amounts may not add due to rounding. BOSTON SCIENTIFIC CORPORATION Q4 and FY 2025 GUIDANCE RECONCILIATIONS (Unaudited) Net Sales Q4 2025 Estimate (Low) (High) Full Year 2025 Estimate Reported growth 14.5   % 16.5   % ~20.0% Impact of foreign currency fluctuations (2.0) % (2.0) % ~(1.0)% Operational growth 12.5   % 14.5   % ~19.0% Impact of certain acquisitions/divestitures (1.5) % (1.5) % ~(3.5)% Organic growth 11.0   % 13.0   % ~15.5% Earnings per Share Q4 2025 Estimate Full Year 2025 Estimate (Low) (High) (Low) (High) GAAP results $ 0.48   $ 0.52   $ 1.97   $ 2.01   Amortization expense 0.13  0.13  0.51  0.51  Acquisition/divestiture-related net charges (credits) 0.04  0.04  0.15  0.15  Restructuring and restructuring-related net charges (credits) 0.07  0.05  0.22  0.20  Other adjustments 0.04  0.04  0.18  0.18  Adjusted results $ 0.77   $ 0.79   $ 3.02   $ 3.04   Amounts may not add due to rounding. Use of Non-GAAP Financial Measures To supplement our unaudited consolidated financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share (EPS) that exclude certain charges (credits); operational net sales, which exclude the impact of foreign currency fluctuations; and organic net sales, which exclude the impac